Tony W. Ho
2018
In 2018, Tony W. Ho earned a total compensation of $4.1M as EVP, Research and Development at CRISPR Therapeutics AG, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $258,321 |
|---|---|
| Option Awards | $3,466,189 |
| Salary | $414,980 |
| Other | $9,625 |
| Total | $4,149,115 |
Ho received $3.5M in option awards, accounting for 84% of the total pay in 2018.
Ho also received $258.3K in non-equity incentive plan, $415K in salary and $9.6K in other compensation.
Rankings
In 2018, Tony W. Ho's compensation ranked 2,660th out of 14,244 executives tracked by ExecPay. In other words, Ho earned more than 81.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,660 out of 14,244 | 81st |
Division Manufacturing | 985 out of 5,765 | 83rd |
Major group Chemicals And Allied Products | 337 out of 2,128 | 84th |
Industry group Drugs | 275 out of 1,817 | 85th |
Industry Biological Products, Except Diagnostic Substances | 57 out of 339 | 83rd |
Source: SEC filing on April 30, 2019.
Ho's colleagues
We found four more compensation records of executives who worked with Tony W. Ho at CRISPR Therapeutics AG in 2018.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019